Gilead Sciences Acquires Investigational HIV Vaccine Assets from AELIX Therapeutics

Acquisition:
Gilead Sciences has acquired the investigational assets for the HTI therapeutic HIV vaccine from AELIX Therapeutics, a biopharmaceutical company based in Barcelona, Spain[1][2].

HTI Immunogen:
The HTI immunogen was designed at IrsiCaixa by researchers Christian Brander, Beatriz Mothe, and Anuska Llano as part of the HIVACAT program. It aims to redirect the immune response toward the most vulnerable regions of HIV[1][2].

Clinical Trials:
The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials, indicating potential for further development as part of an HIV cure strategy[1][2].

Gilead Sciences:
Gilead Sciences is a leader in HIV treatment, prevention, and cure research, with a history of developing innovative medicines for life-threatening diseases[3].

Collaboration:
The acquisition highlights the collaboration between scientific research and business innovation in transforming discoveries into tangible solutions for society[1][4].

Future Development:
The acquisition will enable further progress toward the development of a transformative strategy against HIV, leveraging Gilead Sciences' capabilities and resources[1][2].